Shigellosis, commonly known asbacillary dysentery, is caused by Shigella bacteria that spreads through contaminated food and water or direct person-to-person contact. Symptoms include diarrhea, fever, and stomach cramps starting a day or two after exposure to bacteria. Shigellosis can easily spread in settings like day care centers, schools, camps and even homes. Vaccines help prevent shigellosis and its complications like seizures, dehydration or hemolytic-uremic syndrome. Currently, there are no licensed Shigella vaccines available for routine use.
The global Shigella Vaccines Market is estimated to be valued at US$ 574.20 mn or Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics: One of the major drivers of the Shigella Vaccines Market is rising government initiatives for preventing shigellosis. Government bodies globally recognize the socio-economic burden of shigellosis and hence support research and development of effective Shigella vaccines. For instance, in 2021, Wellcome Trust and the Indian government's Department of Biotechnology announced funding of US$ 8 million for advancing clinical development of an oral Shigella vaccine by MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. Strong R&D activity for developing novel vaccine candidates is another factor fueling market growth. Currently, there are multiple vaccine candidates in preclinical and clinical trial pipeline being developed by companies like Novartis and GSK. If approved, these new products will capture significant market share in the coming years.
SWOT Analysis
Strength: Shigella vaccines represent a promising approach for preventing shigellosis. Ongoing clinical trials for Shigella vaccines show promising results with acceptable safety and immunogenicity profiles. Development of an effective Shigella vaccine could potentially prevent millions of cases and save thousands of lives each year.
Weakness: Developing an effective Shigella vaccine is challenging due to the multiple Shigella serotypes that cause disease. Clinical efficacy against all circulating serotypes needs to be demonstrated before widespread use. High development costs and regulatory hurdles for licensure present challenges.
Opportunity: The global burden of shigellosis, particularly in low-income countries, represents a major public health problem. An effective and affordable Shigella vaccine could potentially control the disease in endemic countries. Recent advances in conjugate vaccine technologies extend opportunities for development of multivalent Shigella vaccines.
Threats: Potential emergence of antibiotic-resistant Shigella strains could undermine treatment of infections and increase the need for prevention with vaccines. However, epidemiological changes or lack of funding support could reduce commercial viability of vaccines. Competition from other enteric vaccine candidates may impact uptake.
Key Takeaways
The global Shigella vaccines market is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis indicates that Asia Pacific region currently dominates the market and is expected to continue its dominance over the forecast period. Factors such as high disease incidence, supportive government programs for immunization, and presence of major players driving clinical trials are boosting the regional market.
Key players operating in the Shigella vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. MSD Wellcome Trust Hilleman Laboratories is currently conducting phase 3 clinical trials of an investigational conjugate vaccine candidate against Shigella in India, which if successful could lead to its market approval and introduction.
The global Shigella Infection Treatment Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
1.1 million falls for death, about 61% of all deaths attributable to shigellosis involved children younger than 5 years.
The prevalence in developing countries is 20 times greater than that in developed countries.
Innovative strategies, including the development of vaccines against the most common serotypes, could provide substantial benefits.
There is room for optimism as advances in biotechnology have enabled the development of a new generation of candidate vaccines that show great promise for the prevention of Shigella infection.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Shigella Infection Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/shigella-infection-treatment-market/download-sampleMarket DynamicsGlobal cases are estimated to be 164.7 million per year, 98% of which occur in developing countries.
1.1 million falls for death, about 61% of all deaths attributable to shigellosis involved children younger than 5 years.
The prevalence in developing countries is 20 times greater than that in developed countries.
Innovative strategies, including the development of vaccines against the most common serotypes, could provide substantial benefits.
There is room for optimism as advances in biotechnology have enabled the development of a new generation of candidate vaccines that show great promise for the prevention of Shigella infection.
